Exagen Inc. NASDAQ:XGN

Exagen stock price today

$9.66
+4.95
+105.1%
Financial Health
0
1
2
3
4
5
6
7
8
9

Exagen stock price monthly change

+144.04%
month

Exagen stock price quarterly change

+144.04%
quarter

Exagen stock price yearly change

+135.50%
year

Exagen key metrics

Market Cap
86.51M
Enterprise value
13.44M
P/E
-0.85
EV/Sales
0.20
EV/EBITDA
-0.20
Price/Sales
0.63
Price/Book
0.97
PEG ratio
0.01
EPS
-1.09
Revenue
55.73M
EBITDA
-16.69M
Income
-19.36M
Revenue Q/Q
28.36%
Revenue Y/Y
16.70%
Profit margin
-109.32%
Oper. margin
-105.42%
Gross margin
44.38%
EBIT margin
-105.42%
EBITDA margin
-29.95%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Exagen stock price history

Exagen stock forecast

Exagen financial statements

Average Price Target
Last Year

$5

Potential downside: -48.24%

Based on estimate of 1 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Exagen Inc. (NASDAQ:XGN): Profit margin
Jun 2023 14.13M -5.01M -35.46%
Sep 2023 13.41M -5.41M -40.36%
Dec 2023 13.76M -5.57M -40.49%
Mar 2024 14.41M -3.36M -23.31%
0%
Yield TTM
Exagen Inc. (NASDAQ:XGN): Payout ratio
Payout ratio 0%
Exagen Inc. (NASDAQ:XGN): Dividend Yield
2019 2.11%
2020
2021
2022
2023
Exagen Inc. (NASDAQ:XGN): Debt to assets
Jun 2023 64178000 32.27M 50.29%
Sep 2023 60928000 33.42M 54.86%
Dec 2023 56944000 34.25M 60.15%
Mar 2024 50808000 30.81M 60.65%
Exagen Inc. (NASDAQ:XGN): Cash Flow
Jun 2023 -10.15M -322K -10.24M
Sep 2023 -2.90M -2K -108K
Dec 2023 8.34M -84K -220K
Mar 2024 -9.04M -86K -100K

Exagen alternative data

Exagen Inc. (NASDAQ:XGN): Employee count
Aug 2023 199
Sep 2023 199
Oct 2023 199
Nov 2023 199
Dec 2023 199
Jan 2024 199
Feb 2024 199
Mar 2024 174
Apr 2024 174
May 2024 174
Jun 2024 174
Jul 2024 174

Exagen other data

29.38% -11.23%
of XGN is owned by hedge funds
5.01M -1.91M
shares is hold by hedge funds

Exagen Inc. (NASDAQ:XGN): Insider trades (number of shares)
Period Buy Sel
Feb 2024 0 6738
Mar 2024 0 12784
May 2024 40401 0
Nov 2024 46603 200000
Transaction Date Insider Security Shares Price per share Total value Source
Sale
NMSIC CO-INVESTMENT FUND, L.P. 10 percent owner
Common Stock 200,000 $3.3 $660,000
Purchase
BLACK JEFFREY G. officer: Chief Financial Officer
Common Stock 22,298 $2.98 $66,448
Purchase
ABALLI JOHN director, officer: President an..
Common Stock 24,305 $2.81 $68,297
Purchase
ABALLI JOHN director, officer: President an..
Common Stock 40,401 $1.92 $77,570
Sale
ADAWI KAMAL officer: CFO and Corporate Secr..
Common Stock 9,297 $1.91 $17,748
Sale
ADAWI KAMAL officer: CFO and Corporate Secr..
Common Stock 3,487 $1.91 $6,660
Sale
ADAWI KAMAL officer: CFO and Corporate Secr..
Common Stock 6,738 $1.95 $13,132
Sale
ABALLI JOHN director, officer: President an..
Common Stock 33,819 $1.75 $59,014
Purchase
TULLIS JAMES L L 10 percent owner
Common Stock 167 $3.11 $520
Sale
HAZELTINE MARK officer: Chief Business Officer
Common Stock 3,667 N/A N/A
Patent
Application
Filling date: 12 May 2022 Issue date: 1 Sep 2022
Application
Filling date: 5 Apr 2021 Issue date: 22 Jul 2021
Insider Compensation
Mr. Fortunato Rocca (1961) Chief Executive Officer, Pres & Director $1,080,000
Mr. Kamal Adawi M.S., MBA (1979) Chief Financial Officer & Corporation Sec.
$620,300
Dr. Debra Jeske Zack (1957) Chief Medical Officer $576,660
Thursday, 12 December 2024
globenewswire.com
Thursday, 14 November 2024
globenewswire.com
Tuesday, 12 November 2024
seekingalpha.com
zacks.com
Monday, 21 October 2024
globenewswire.com
Wednesday, 4 September 2024
globenewswire.com
Thursday, 29 August 2024
zacks.com
Monday, 26 August 2024
zacks.com
Friday, 9 August 2024
zacks.com
Thursday, 8 August 2024
zacks.com
Monday, 5 August 2024
zacks.com
Friday, 2 August 2024
globenewswire.com
Thursday, 1 August 2024
globenewswire.com
Monday, 22 July 2024
globenewswire.com
Thursday, 13 June 2024
zacks.com
Monday, 10 June 2024
benzinga.com
zacks.com
Monday, 13 May 2024
Seeking Alpha
Zacks Investment Research
Monday, 18 March 2024
Seeking Alpha
Zacks Investment Research
Thursday, 7 March 2024
GlobeNewsWire
Tuesday, 6 February 2024
Zacks Investment Research
Monday, 20 November 2023
Seeking Alpha
Monday, 30 October 2023
GlobeNewsWire
Tuesday, 12 September 2023
GlobeNewsWire
Monday, 7 August 2023
Zacks Investment Research
Tuesday, 25 July 2023
GlobeNewsWire
Monday, 15 May 2023
Seeking Alpha
Zacks Investment Research
  • What's the price of Exagen stock today?

    One share of Exagen stock can currently be purchased for approximately $9.66.

  • When is Exagen's next earnings date?

    Unfortunately, Exagen's (XGN) next earnings date is currently unknown.

  • Does Exagen pay dividends?

    No, Exagen does not pay dividends.

  • How much money does Exagen make?

    Exagen has a market capitalization of 86.51M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 15.33% to 52.55M US dollars.

  • What is Exagen's stock symbol?

    Exagen Inc. is traded on the NASDAQ under the ticker symbol "XGN".

  • What is Exagen's primary industry?

    Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.

  • How do i buy shares of Exagen?

    Shares of Exagen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Exagen's key executives?

    Exagen's management team includes the following people:

    • Mr. Fortunato Rocca Chief Executive Officer, Pres & Director(age: 64, pay: $1,080,000)
    • Mr. Kamal Adawi M.S., MBA Chief Financial Officer & Corporation Sec.(age: 46, pay: $620,300)
    • Dr. Debra Jeske Zack Chief Medical Officer(age: 68, pay: $576,660)
  • How many employees does Exagen have?

    As Jul 2024, Exagen employs 174 workers.

  • When Exagen went public?

    Exagen Inc. is publicly traded company for more then 5 years since IPO on 19 Sep 2019.

  • What is Exagen's official website?

    The official website for Exagen is exagen.com.

  • Where are Exagen's headquarters?

    Exagen is headquartered at 1261 Liberty Way, Vista, CA.

  • How can i contact Exagen?

    Exagen's mailing address is 1261 Liberty Way, Vista, CA and company can be reached via phone at +7 605601501.

  • What is Exagen stock forecast & price target?

    Based on 1 Wall Street analysts` predicted price targets for Exagen in the last 12 months, the avarage price target is $5. The average price target represents a -48.24% change from the last price of $9.66.

Exagen company profile:

Exagen Inc.

exagen.com
Exchange:

NASDAQ

Full time employees:

174

Industry:

Medical - Diagnostics & Research

Sector:

Healthcare

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

1261 Liberty Way
Vista, CA 92081

CIK: 0001274737
ISIN: US30068X1037
CUSIP: 30068X103